Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Filings indexed 1,256 across all filing types
Latest filing 2026-04-10 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2026-04-10 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2026-04-10 English
General Updates
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the appointment and promotion of senior management personnel. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events including changes in senior management. The content details the appointment of a Medical Director and promotion of a Director within the company, including their profiles and effective dates. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of changes in senior management positions, fitting the category of Board/Management Information (MANG). The document length (7082 characters) supports it being a detailed announcement rather than a brief notice or a report publication announcement.
2026-03-31 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2026-03-31 English
Shareholders meeting
Regulatory Filings
2026-03-31 English
Please find the enclosed intimation of the Company as per the captioned subject for your reference.
Regulatory Filings
2026-03-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.